Ted Davis to Succeed Amy Tseng as President and CEO of TissueTech

TissueTech has named Ted Davis as the company’s new president and CEO. Mr. Davis, a seasoned biologics and orthopedics executive, takes the helm of an emerging company experiencing exponential growth, succeeding TissueTech founder and former CEO Amy Tseng, who retired January 3. Ms. Tseng remains a member of the company’s board of directors.

“It is an honor to be only the second CEO in TissueTech’s 25-year history. I have watched the company for more than a decade and have been impressed with its platform technology, clinical outcomes, and surgeon support,” said Mr. Davis. “With the addition of ongoing clinical programs to secure biologics license applications for indications to address significant unmet clinical needs in the ophthalmology, orthopedics, and wound management segments, TissueTech is poised to secure its position as a leader in regenerative medicine—now and into the future.”

Mr. Davis most recently served for 5 years as president and CEO of Active Implants LLC, a medical device company focused on the knee preservation segment of sports medicine. He began his career with a decade in the life sciences venture capital field, then transitioned into operating leadership roles at Wright Medical Technology and MicroPort Orthopedics before joining Active Implants, where he is still on the board of directors. Mr. Davis also currently serves on the boards of Axis Spine Technologies, and SIbone, Inc.

Since its inception in 1997, TissueTech has pioneered the clinical application of human placental tissues. Today, more than 600,000 patients have been treated with TissueTech products and the company’s scientific and clinical achievements have been documented in more than 300 peer-reviewed publications.